1. Home
  2. FINW vs ADAG Comparison

FINW vs ADAG Comparison

Compare FINW & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FINW

FinWise Bancorp

HOLD

Current Price

$14.50

Market Cap

235.7M

Sector

Finance

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.97

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINW
ADAG
Founded
1999
2011
Country
United States
China
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.7M
254.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FINW
ADAG
Price
$14.50
$3.97
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
20.8K
132.2K
Earning Date
04-30-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
21.51
N/A
EPS
0.20
N/A
Revenue
N/A
N/A
Revenue This Year
$160.48
N/A
Revenue Next Year
$35.27
N/A
P/E Ratio
$72.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.82
$1.44
52 Week High
$22.49
$4.75

Technical Indicators

Market Signals
Indicator
FINW
ADAG
Relative Strength Index (RSI) 53.22 58.69
Support Level $12.82 $3.16
Resistance Level $17.39 $3.99
Average True Range (ATR) 0.49 0.35
MACD 0.20 0.05
Stochastic Oscillator 93.01 70.94

Price Performance

Historical Comparison
FINW
ADAG

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: